TEL AVIV, Israel and BETHESDA, Maryland, Feb. 19, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB:CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has submitted a protocol for the Helsinki Committee to conduct a nationwide study which will apply Cannabics' high throughput screening platform to analyze the anti-tumor properties of cannabinoid compounds and chemotherapies on fresh biopsies. If the proposed study is approved, Cannabics will be able to obtain, upon patients' consent, a live biopsy and blood sample and perform drug sensitivity and drug resistance tests.
This protocol is part of Cannabics' ongoing mission to commercialize its personalized diagnostics and apply its technology to Cannabinoids and chemotherapy, which in turn will provide doctors and their patients' supportive data for more informed treatment decisions.
Dr. Eyal Ballan, CTO and Co-Founder of Cannabics, said, "This ex-vivo study is a continuum of our in-vitro study searching for apoptotic effects of Cannabinoids in a personalized manner. We believe it is the first time Cannabinoids are being tested on live biopsies. Our aim is to incorporate cannabis growers, locally and globally, and invest further in mapping their cannabinoid repertoire in order to provide individual tailored treatments for cancer patients."
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. (CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient's profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer. For more information, please visit www.cannabics.com.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. For example, we are using forward-looking statements when we discuss the protocol and the proposed clinical study, the performance of drug sensitivity and drug resistance tests if the clinical study is approved, our ongoing mission to commercialize our personalized diagnostics and potentially provide doctors and their patients supportive data for more informed treatment decisions, the belief that the protocol further supports efforts in establishing a library of cannabinoid compositions and our aim to incorporate cannabis growers, locally and globally, and invest further in mapping their cannabinoid repertoire in order to provide individual tailored treatments for cancer patients. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc. which are condoned by the Company must emanate from the Company itself and bear our name as its source.
SOURCE Cannabics Pharmaceuticals Inc.